ZA992255B - Antitumor synergetic composition. - Google Patents

Antitumor synergetic composition.

Info

Publication number
ZA992255B
ZA992255B ZA9902255A ZA992255A ZA992255B ZA 992255 B ZA992255 B ZA 992255B ZA 9902255 A ZA9902255 A ZA 9902255A ZA 992255 A ZA992255 A ZA 992255A ZA 992255 B ZA992255 B ZA 992255B
Authority
ZA
South Africa
Prior art keywords
antitumor
synergetic composition
synergetic
composition
antitumor synergetic
Prior art date
Application number
ZA9902255A
Other languages
English (en)
Inventor
Cristina Geroni
Marina Ripamonti
Michele Caruso
Antonino Suarato
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of ZA992255B publication Critical patent/ZA992255B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9902255A 1998-03-24 1999-03-23 Antitumor synergetic composition. ZA992255B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806324.1A GB9806324D0 (en) 1998-03-24 1998-03-24 Antitumour synergetic composition

Publications (1)

Publication Number Publication Date
ZA992255B true ZA992255B (en) 1999-10-05

Family

ID=10829188

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9902255A ZA992255B (en) 1998-03-24 1999-03-23 Antitumor synergetic composition.

Country Status (29)

Country Link
US (1) US6403563B1 (cs)
EP (1) EP1067941B1 (cs)
JP (1) JP2002507571A (cs)
KR (1) KR20010034619A (cs)
CN (2) CN1150002C (cs)
AR (1) AR018166A1 (cs)
AT (1) ATE271388T1 (cs)
AU (1) AU758191B2 (cs)
BR (1) BR9908391A (cs)
CA (1) CA2324610A1 (cs)
CZ (1) CZ295368B6 (cs)
DE (1) DE69918819T2 (cs)
DK (1) DK1067941T3 (cs)
EA (1) EA003134B1 (cs)
ES (1) ES2226366T3 (cs)
GB (1) GB9806324D0 (cs)
HU (1) HUP0101615A3 (cs)
ID (1) ID26091A (cs)
IL (1) IL138035A0 (cs)
MY (1) MY133016A (cs)
NO (1) NO20004703L (cs)
NZ (1) NZ507570A (cs)
PL (1) PL343098A1 (cs)
PT (1) PT1067941E (cs)
SI (1) SI1067941T1 (cs)
TW (1) TW576740B (cs)
UA (1) UA63000C2 (cs)
WO (1) WO1999048503A1 (cs)
ZA (1) ZA992255B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820065B1 (en) * 1998-03-18 2004-11-16 Ascom Hasler Mailing Systems Inc. System and method for management of postage meter licenses
GB9904387D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
GB9926843D0 (en) * 1999-11-12 2000-01-12 Pharmacia & Upjohn Spa Lipid complex of alkycyclines
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
US20090107925A1 (en) * 2007-10-31 2009-04-30 Chevron U.S.A. Inc. Apparatus and process for treating an aqueous solution containing biological contaminants
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
EP2721181B1 (en) 2011-06-17 2019-12-18 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
WO2013096843A1 (en) 2011-12-21 2013-06-27 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
CA3126823C (en) 2012-06-07 2023-04-04 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
ES2777228T3 (es) 2013-04-05 2020-08-04 Myriad Genetics Inc Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
KR20160132076A (ko) 2014-03-07 2016-11-16 몰리코프 미네랄스, 엘엘씨 비소 제거 특성이 뛰어난 세륨(iv) 산화물
PT3180447T (pt) 2014-08-15 2020-06-18 Myriad Genetics Inc Métodos e materiais para avaliar a deficiência de recombinação homóloga
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114549D0 (en) * 1991-07-05 1991-08-21 Erba Carlo Spa Mono and bis alkylamino-anthracyclines
GB9325417D0 (en) * 1993-12-13 1994-02-16 Erba Carlo Spa 3'- aziridino-anthracycline derivatives

Also Published As

Publication number Publication date
JP2002507571A (ja) 2002-03-12
EP1067941A1 (en) 2001-01-17
ES2226366T3 (es) 2005-03-16
KR20010034619A (ko) 2001-04-25
DE69918819T2 (de) 2005-08-18
US6403563B1 (en) 2002-06-11
DK1067941T3 (da) 2004-11-29
PT1067941E (pt) 2004-12-31
IL138035A0 (en) 2001-10-31
WO1999048503A1 (en) 1999-09-30
UA63000C2 (en) 2004-01-15
NO20004703D0 (no) 2000-09-20
AU758191B2 (en) 2003-03-20
NO20004703L (no) 2000-09-20
ID26091A (id) 2000-11-23
SI1067941T1 (en) 2005-02-28
CZ295368B6 (cs) 2005-07-13
GB9806324D0 (en) 1998-05-20
CZ20003493A3 (cs) 2001-02-14
BR9908391A (pt) 2000-10-31
ATE271388T1 (de) 2004-08-15
NZ507570A (en) 2003-01-31
TW576740B (en) 2004-02-21
CN1528334A (zh) 2004-09-15
EA200000978A1 (ru) 2001-02-26
EP1067941B1 (en) 2004-07-21
HUP0101615A2 (hu) 2001-10-28
EA003134B1 (ru) 2003-02-27
MY133016A (en) 2007-10-31
DE69918819D1 (de) 2004-08-26
AU3331499A (en) 1999-10-18
PL343098A1 (en) 2001-07-30
CA2324610A1 (en) 1999-09-30
AR018166A1 (es) 2001-10-31
HUP0101615A3 (en) 2002-12-28
CN1294516A (zh) 2001-05-09
CN1150002C (zh) 2004-05-19

Similar Documents

Publication Publication Date Title
ZA992255B (en) Antitumor synergetic composition.
ZA996185B (en) Sulfanylsilanes.
ZA200005136B (en) Dihydropyrimides.
ZA9811959B (en) Ibuprofen composition.
ZA991014B (en) Pesticidal compositions.
ZA99254B (en) Benzosulfone derivatives.
IL143939A0 (en) Combination chemotherapy
ZA991272B (en) Novel thiobenzamides.
ZA200005510B (en) Pharmaceutical composition.
ZA993883B (en) Adhesive compositions.
ZA991550B (en) Cyclohexanediole derivatives.
ZA993197B (en) Pesticidal composition.
ZA993123B (en) Trisresorcinyltriazines.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
GB9802041D0 (en) Complexing compositions
ZA995239B (en) Pesticidal compositions.
ZA200006118B (en) Novel composition.
ZA99890B (en) Pharmaceutical compositions.
ZA200000192B (en) Novel composition.
ZA99925B (en) Composition.
ZA993495B (en) Metallic articles.
ZA200005335B (en) Antitumor agents.
ZA996936B (en) Railbreak indicating arrangement.
ZA200100718B (en) Pesticidal compositions.
ZA200104446B (en) Food composition.